Discover investment opportunities in Best Biotech Stocks To Buy using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Biotech Stocks To Buy using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Biotech Stocks To Buy using our Smart AI Filter.
9 stocks found for "Best Biotech Stocks To Buy"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.63 | ±35.0% | 27.1 | 0.00% | |||
0.60 | ±39.2% | 20.8 | 0.00% | |||
0.34 | ±25.2% | 8.0 | 0.00% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.45 | ±25.0% | 14.4 | 3.19% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
0.83 | ±70.5% | -3.5 | 0.00% | |||
0.36 | ±26.9% | 24.5 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now?
Read morePresident Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read moreQ: What sector-specific risks should investors be aware of for biotechnology stocks like Amgen (AMGN) and Biogen (BIIB)?
A: Biotechnology stocks, such as Amgen (AMGN) and Biogen (BIIB), face unique risks including regulatory approvals, patent expirations, and high research and development costs. These factors can result in volatility in stock performance, and investors should monitor the clinical trial phases and pipeline progress closely.
Q: How does Vertex Pharmaceuticals (VRTX) typically perform during economic downturns?
A: Vertex Pharmaceuticals (VRTX), like many biotech firms, may be less impacted by economic downturns due to the non-cyclical nature of the healthcare sector. However, investor sentiment and market conditions can influence stock performance, so historical resilience does not guarantee future stability.
Q: Why might some investors be attracted to Gilead Sciences (GILD) for dividend income?
A: Gilead Sciences (GILD) offers dividends, appealing to income-focused investors. While its yield is attractive, sustainability depends on cash flow and earnings, making dividend analysis crucial. Past performance isn't indicative of future results, so careful evaluation is recommended.
Q: Are there any competitive advantages for Moderna (MRNA) when compared with traditional pharmaceutical companies?
A: Moderna (MRNA) focuses on mRNA-based vaccine technology, offering a cutting-edge approach that differentiates it from traditional pharmaceuticals. Its rapid development and contribution to COVID-19 vaccines showcase innovation potential, though ongoing success depends on future applications.
Q: What balanced investment strategy might incorporate Illumina (ILMN) amidst its growth trajectory?
A: Illumina (ILMN) appeals to growth-oriented investors due to its leadership in genomic sequencing. However, balancing with stable sectors can mitigate inherent biotech volatility. Portfolio diversification could include defensive stocks alongside growth leaders like ILMN.
Q: How do regulatory changes impact biotechnology companies like Regeneron Pharmaceuticals (REGN)?
A: Regulatory changes can significantly influence Regeneron Pharmaceuticals (REGN) by affecting drug approval processes and compliance costs. Investors should stay informed about evolving healthcare regulations since these changes may impact timelines and profitability.